MedPath

Feasibility study of weekly paclitaxel plus gemcitabine for metastatic and recurrent breast cancer with negative HER2

Not Applicable
Conditions
Breast cancer
Registration Number
JPRN-UMIN000007445
Lead Sponsor
Kyushu Breast Cancer Study Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1.Allergy to clemohol EL 2.Significant interstitial pneumonia or pulmonary fibrosis seen by chest radiograph and presence of symptoms associated with them 3.Pregnant or lactation women, or women with suspected pregnancy 4.Symptomatic CNS metastasis 5.Infection which needs treatment 6.Poorly controlled pleural effusion or peritoneal effusion 7.Patients judged by the investigator to be unfit for the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
response rate, safety
Secondary Outcome Measures
NameTimeMethod
response duration, time to progression, overall survival
© Copyright 2025. All Rights Reserved by MedPath